Stephen Johnston, a medical oncologist at the Royal Marsden Hospital in London, outlines the data supporting CDK4/6 inhibitors plus endocrine therapy in patients with high-risk, hormone receptor positive, HER2-negative breast cancer. This is especially important for patients with high-risk disease, where adding another therapy could decrease their risk of disease recurrence.
Highlights
- Most recent efficacy and safety data from monarchE and NATALEE presented at ESMO 2025
- Seven year analysis of monarchE trial
- Five year analysis of NATALEE trial
- Dose reduction data
Want to learn more? Access additional EBC medical education resources here.
MMAT-00769 © 2026 Lilly USA, LLC. All rights reserved. 